Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

12.95 +0.40 (+3.19%)
Delayed Quote Updated: 10:41 AM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
3 Biotech Stocks Under $10 to Add to Your Buy List ↗
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. 
Via InvestorPlace
News headline image
Sunday Memo - Dec. 5 ↗
The market rout was worldwide last week. 
Via Talk Markets
News headline image
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Full Year 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
News headline image
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
From AbCellera Biologics Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
News headline image
Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19 ↗
The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized... 
Via Benzinga
News headline image
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
From AbCellera
Via Business Wire
News headline image
Top Biotech Stocks: Trading Opportunities For Next Week ↗
A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns. 
Via Talk Markets
News headline image
AbCellera Announces Changes to Its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Futures Rebound From Friday Rout As Omicron Fears Ease ↗
S&P futures and European stocks rebounded from Friday’s selloff while Asian shares fell, as investors took comfort in reports from South Africa which said initial data doesn’t show a surge of... 
Via Talk Markets
Topics Stocks
News headline image
Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns ↗
The FDA has expanded the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) bamlanivimab and etesevimab administered together to include... 
Via Benzinga
News headline image
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail? ↗
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
News headline image
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19 ↗
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
News headline image
Friday Markets Coverage ↗
Today markets are suffering alongside Austria which locked down against Covid-19 again. 
Via Talk Markets
News headline image
AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript ↗
ABCL earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
News headline image
AbCellera Reports Q3 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
How Bad Are AbCellera Biologics's Earnings? | Return On Capital Employed ↗
Benzinga Pro data, AbCellera Biologics (NASDAQ:ABCL) reported Q2 sales of $27.64 million. Earnings fell to a loss of $7.03 million, resulting in a 104.45% decrease from last... 
Via Benzinga
News headline image
AbCellera Announces Virtual Presentations at Investor Conferences in November
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Why AbCellera Biologics Stock Sank 21.6% in October ↗
The biotech is now down roughly 56% across 2021's trading. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>